Breast Cancer Update, Issue 1, 2019


BCU119

Interview with Eric P Winer, MD

Track 1: Case: A 57-year-old woman presents with de novo ER-positive, HER2-negative metastatic breast cancer (mBC)
Track 2: Clinical experience with and differential side-effect profiles of CDK4/6 inhibitors
Track 3: Efficacy of everolimus in patients with ER-positive, HER2-negative mBC; management of treatment-associated mucositis
Track 4: Response to capecitabine in patients with ER-positive, HER2-negative lobular BC and leptomeningeal metastases
Track 5: First-line therapy options for patients with ER-positive, HER2-negative mBC
Track 6: Choosing among the FDA-approved CDK4/6 inhibitors
Track 7: Monitoring white blood cell counts in patients receiving CDK4/6 inhibitors
Track 8: Consideration of CDK4/6 inhibitors in the (neo)adjuvant setting
Track 9: PALLAS: An ongoing Phase III trial of standard adjuvant endocrine therapy with or without palbociclib for ER-positive, HER2-negative early BC
Track 10: Case: A 60-year-old woman with moderately differentiated ER-positive, HER2-negative BC and 1 positive node receives a 21-gene assay Recurrence Score® (RS) of 20
Track 11: TAILORx: Results of a Phase III trial of chemoendocrine therapy versus endocrine therapy alone for patients with ER-positive, HER2-negative, node-negative BC and an intermediate RS
Track 12: Applying the TAILORx trial results to the care of patients with ER-positive, HER2-negative BC and limited nodal involvement
Track 13: Use of genomic assays to help guide treatment decision-making
Track 14: Seven-year follow-up from the APT trial: Adjuvant paclitaxel and trastuzumab for HER2-positive, node-negative BC
Track 15: Evaluation of neoadjuvant paclitaxel/trastuzumab with pertuzumab for Stage II/III BC
Track 16: Consideration of (neo)adjuvant docetaxel/carboplatin/trastuzumab and pertuzumab versus paclitaxel/trastuzumab for early-stage ER-negative, HER2-positive BC
Track 17: First-line paclitaxel/trastuzumab/pertuzumab for ER-negative, HER2-positive mBC
Track 18: PERTAIN: Results of a Phase II trial of first-line trastuzumab and an aromatase inhibitor with or without pertuzumab for ER-positive, HER2-positive locally advanced or metastatic BC
Track 19: Case: A 56-year-old woman with previously treated ER-positive, HER2-positive BC experiences disease progression and is found on biopsy to have ER-negative, HER2-positive disease with a PI3-kinase mutation
Track 20: Efficacy of the investigational alpha-specific PI3 kinase inhibitor alpelisib (BYL719) in combination with fulvestrant for ER-positive, HER2-negative mBC
Track 21: Activity and tolerability of the HER2-selective tyrosine kinase inhibitor tucatinib in patients with ER-negative, HER2-positive advanced BC
Track 22: Response and tolerability of T-DM1 and pembrolizumab in patients with ER-negative, HER2-positive mBC
Track 23: IMpassion130: Results of a Phase III study of first-line nab paclitaxel alone or in combination with atezolizumab for locally advanced or metastatic triple-negative BC (TNBC)
Track 24: Choosing between nab and solvent-based paclitaxel
Track 25: Use of next-generation sequencing for patients with mBC
Track 26: Approach to BRCA testing for patients with mBC
Track 27: Case: A 40-year-old woman is diagnosed with locally advanced TNBC with a BRCA1 mutation
Track 28: Rationale for combining immune checkpoint inhibitors with olaparib or chemotherapy

Interview with Daniel F Hayes, MD

Track 1: Weighing the risks and benefits of adjuvant chemotherapy for patients with BC
Track 2: Prospective validation of the 21-gene assay RS for ER-positive, HER2-negative BC
Track 3: Critical evaluation of the Phase III TAILORx trial results: Adjuvant chemotherapy guided by the 21-gene assay RS for ER-positive, node-negative BC
Track 4: Clinical basis for the ongoing Phase III RxPONDER trial evaluating standard adjuvant endocrine therapy with or without chemotherapy for patients with ER-positive, HER2-negative BC, 1 to 3 positive nodes and a RS of 25 or lower
Track 5: Application of the TAILORx trial results in clinical practice
Track 6: Updated results from the TEXT and SOFT trials: Adjuvant endocrine therapy with ovarian function suppression for premenopausal women with ER-positive, HER2-negative BC
Track 7: Importance of menopausal status, number of positive nodes and RS in the selection of an adjuvant endocrine therapy
Track 8: Use of genomic assays to guide neoadjuvant therapy decision-making
Track 9: Selection of hormonal therapy versus chemotherapy for patients with symptomatic ER-positive, HER2-negative mBC
Track 10: Activity and tolerability of CDK4/6 inhibitors for ER-positive, HER2-negative mBC
Track 11: Comparison of FDA-approved CDK4/6 inhibitors: Efficacy, tolerability and dosing
Track 12: Perspective on the investigation of immune checkpoint inhibitors in combination with chemotherapy for patients with metastatic TNBC
Track 13: Role of PARP inhibitors for patients with mBC and a germline BRCA mutation
Track 14: Use of trastuzumab/pertuzumab in the adjuvant setting and neratinib in the extended-adjuvant setting for patients with HER2-positive BC

Interview with Ingrid A Mayer, MD, MSCI

Track 1: Case: A 43-year-old woman who previously declined adjuvant therapy for Stage II, ER/PR-positive, HER2-negative BC with 1 positive node presents 3 years later with symptomatic metastatic disease
Track 2: RxPONDER: An ongoing Phase III trial of standard adjuvant endocrine therapy with or without chemotherapy for patients with ER-positive, HER2-negative BC, 1 to 3 positive nodes and a RS of 25 or lower
Track 3: Perspective on ordering the 21-gene assay for patients with node-positive BC
Track 4: Prognostic and predictive value of the 21-gene assay RS for patients with ER-positive, HER2-negative, node-negative BC
Track 5: Clinical implications of the TAILORx trial results: Adjuvant chemotherapy guided by the 21-gene assay RS for ER-positive, HER2-negative, node-negative BC
Track 6: Discussion of the TAILORx trial results in premenopausal participants
Track 7: Perspective on the use of the 21-gene assay for postmenopausal women with limited nodal involvement
Track 8: TAILORx trial results: Risk of distant recurrence for premenopausal women
Track 9: Use of palliative radiation therapy for pathologic fracture before initiation of CDK4/6 inhibitor-based systemic therapy
Track 10: Strategies to combat primary and acquired resistance to endocrine therapies
Track 11: Magnitude of benefit with the addition of CDK4/6 inhibitors to endocrine therapy for ER-positive, HER2-negative mBC in the first- and second-line settings
Track 12: Exploring the value of continuing therapy with CDK4/6 inhibitors and switching endocrine therapy partner after disease progression
Track 13: Clinical experience with and management of everolimus-associated mucositis
Track 14: Case: A 48-year-old woman with ER-positive, HER2-positive mBC receives neoadjuvant trastuzumab/chemotherapy
Track 15: Factors driving the decision to administer trastuzumab/pertuzumab and/or neratinib to patients with HER2-positive early BC
 
FACULTY
 
Eric P Winer, MD
Senior Vice President for Medical Affairs
Chief, Division of Breast Oncology
Thompson Chair in Breast Cancer Research
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Daniel F Hayes, MD
Stuart B Padnos Professor of
Breast Cancer Research
University of Michigan Rogel Cancer Center
Professor, Internal Medicine
Michigan Medicine
Ann Arbor, Michigan
 
Ingrid A Mayer, MD, MSCI
Ingram Professor of Cancer Research
Professor of Medicine
Leader
VICC Breast Cancer Research Program
Co-Principal Investigator, VICC Breast Cancer SPORE
Division of Hematology-Oncology
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida